In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Effects of successful percutaneous coronary intervention of chronic total occlusions on myocardial perfusion and left ventricular function.

Session Poster session 1

Speaker Stefan Paulus Schumacher

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : SP Schumacher (Amsterdam,NL), WJA Stuijfzand (Amsterdam,NL), PS Biesbroek (Amsterdam,NL), PGHM Raijmakers (Amsterdam,NL), RS Driessen (Amsterdam,NL), P Van Diemen (Amsterdam,NL), R Nijveldt (Amsterdam,NL), AA Lammertsma (Amsterdam,NL), AC Van Rossum (Amsterdam,NL), A Nap (Amsterdam,NL), N Van Royen (Amsterdam,NL), P Knaapen (Amsterdam,NL)

S.P. Schumacher1 , W.J.A. Stuijfzand1 , P.S. Biesbroek1 , P.G.H.M. Raijmakers2 , R.S. Driessen1 , P. Van Diemen1 , R. Nijveldt1 , A.A. Lammertsma2 , A.C. Van Rossum1 , A. Nap1 , N. Van Royen1 , P. Knaapen1 , 1VU University Medical Center, Department of Cardiology - Amsterdam - Netherlands , 2VU University Medical Center, Department of Radiology & Nuclear Medicine - Amsterdam - Netherlands ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 191

Background: Chronic total occlusions (CTO) are observed in up to 30% of patients with known or suspected coronary artery disease. Percutaneous coronary intervention (PCI) of CTO is technically challenging and its salutary effects are questioned.

Purpose: The aim of the present study was to investigate the effects of successful PCI CTO on absolute myocardial blood flow (MBF) and functional recovery.

Methods: Patients with a documented CTO were prospectively examined for ischemia and viability with (15O)H2O positron emission tomography (PET) and late gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR). Sixty-nine consecutive patients, in whom PCI was successful, underwent follow-up PET and CMR after approximately 12 weeks to evaluate potential improvement of MBF as well as regional and global systolic function.

Results: After PCI, stress MBF in the CTO area increased from 1.22±0.36 to 2.40±0.90 mL·min-1·g-1 (p<0.001), whilst stress MBF in the remote area also increased significantly between baseline and follow-up PET (2.58±0.68 to 2.77±0.77 mL·min-1·g-1, p=0.01). The ratio of stress MBF between CTO and remote area was 0.49±0.13 at baseline and increased to 0.87±0.24 at follow-up (p<0.001). MBF defect size of the CTO area decreased from 5.12±1.69 to 1.91±1.75 myocardial segments after PCI (p<0.001). Left ventricular ejection fraction significantly increased (46.4±11.0 vs. 47.5±11.4%, p=0.01) at follow-up, whereas mean systolic wall thickening of the myocardium subtended by the CTO artery did not improve after PCI (p=0.18). There was no relation between the extent of LGE (%) and change of systolic wall thickening at follow up (R=0.01, p=0.69), nor was improvement in stress MBF associated with recovery of systolic wall thickening (R=0.08, p=0.53).

Conclusions: The vast majority of CTO patients with documented ischemia and viability showed significant improvement in stress MBF and a reduction of ischemic burden after successful percutaneous revascularization with only minimal effect on left ventricular ejection fraction.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are